3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
7
Gastrointestinal
7
Genitourinary
4
CNS
3
Breast
3
Gynecologic
2
Other
1
Head & Neck
1
Endocrine
1
Dermatologic
1
Conditions
Prostatic Neoplasms
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Colonic Neoplasms
1
Breast Neoplasms
1
Interventions
Imiquimod
15
Aminolevulinic Acid
8
Fluorouracil
6
Diclofenac
6
3-ingenyl angelate
6
Nivolumab
5
Cryotherapy
5
tirbanibulin
4
methyl 5-aminolevulinate
4
Sirolimus
4
denileukin diftitox
3
aldesleukin
3
Photochemotherapy
3
Ipilimumab
3
Blood Specimen Collection
3
relatlimab
2
Vemurafenib
2
Tacrolimus
2
Prednisone
2
Ointments
2
Methotrexate
2
Immune Checkpoint Inhibitors
2
HhAntag691
2
Gels
2
Cyclosporine
2
Cryosurgery
2
trametinib
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
technetium Tc 99m nanocolloid
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Propofol
×
Dermatologic
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled